(* atai Life sciences Announces
NYC, March 3, 2021 /PRNewswire/ — atai Life Sciences (“atai” or the “Company”), a clinical-stage company that is biopharmaceutical psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by Woodline Partners LP.
atai is excited to welcome Woodline Partners onboard as a investor that is new a good investment company that implements significant equity strategy concentrated mainly in the international Healthcare and tech sectors.
The Series D fundraising saw involvement from current and brand new investors including Ventures that is fearless Edge Capital, Pura Vida Pro LLC, Catalio Capital Management, Michael Auerbach’s Subversive Capital and Highline Capital.
The proceeds from this financing will support the expansion and development of the Company’s diverse drug candidate pipeline and technologies that are enabling. In addition, the funding will give you the runway that is necessary continue advancing its current clinical developments, as well as scale its experienced team in order to continue delivering key milestones.
“This marks a moment that is monumental atai; we carry on our objective challenging the existing means psychological state conditions are addressed. We’ve become better equipped than in the past to speed up the growth of more treatments that are efficacious” said Florian Brand, CEO & co-founder of atai. “With support from our investors, we are determined to improve care and innovate.”
“To achieve our goal of developing treatments that are alternative psychological state problems, we should enable the entire world with your eyesight money for hard times of care,” stated Christian Angermayer. “Moments like this show the significance of our work. It is a step forward, and we thank those continuing to drive this vision so that patients may eventually live more fulfilled lives.”
“We are excited to carry on supporting atai, the company that is only neuropsychiatry today that is thoughtfully pursuing platform diversity alongside scientific depth. The company is well-positioned to deliver on the vision of its founders by creating a new wave of therapies for patients in need” said Jason Camm, Managing Director and Chief Medical Officer of Thiel Capital.
“There is a need for more efficacious treatments to address health that is mental,” stated Matthew Katten, Portfolio Manager at Woodline Partners. “We think atai has generated a position that is leading this space and we are excited to partner with them to drive innovation for improved mental health patient outcomes.”
About atai Life Sciences
atai is a clinical-stage company that is biopharmaceutical to transform the treating psychological state problems. atai was created in 2018 as an answer towards the significant unmet need and not enough innovation into the health treatment landscape that is mental. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other health that is mental. atai’s company model combines capital, technology, medical and regulatory expertise with a focus on psychedelic treatment as well as other medications with differentiated security pages and potential that is therapeutic. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal health that is mental. atai’s mission is always to bridge the space between exactly what the healthcare that is mental currently provides and what patients need. atai is headquartered in Berlin, with offices in New York. For more information, www.atai please visit.life.
atai – Chief Financial Officer
Email: [email protected]
KCSA Strategic Communications
Phone: +1 (212) 896-1265
Email: [email protected]
SOURCE atai Life Sciences